An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele

Oncotarget

Volumn 7, Issue 52, 2016, Pages 86359-86373

  Jochems, Caroline ^a   Hodge, James W ^a   Fantini, Massimo ^a   Fujii, Rika ^a   Morillon, Y Maurice ^a   Greiner, John W ^a   Padget, Michelle R ^a   Tritsch, Sarah R ^a   Tsang, Kwong Yok ^a   Campbell, Kerry S ^b   Klingemann, Hans ^c   Boissel, Laurent ^c   Rabizadeh, Shahrooz ^d   Soon Shiong, Patrick ^c,d   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c NantKwest   (United States)

^d NantWorks LLC   (United States)

Author keywords

ADCC; Cetuximab; High affinity CD16; Immunotherapy; NK lysis

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FC GAMMA RECEPTOR IIIA; FC RECEPTOR; GAMMA INTERFERON; GRANZYME; GRANZYME B; INTERLEUKIN 2; INTERLEUKIN 8; KI 67 ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; PERTUZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TRASTUZUMAB; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IMMUNOGLOBULIN G;

ALLELE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IRRADIATION; NK 92 CELL LINE; TUMOR CELL LINE; ADOPTIVE TRANSFER; ANIMAL; ENZYMOLOGY; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; MALE; MIDDLE AGED; MOUSE; NATURAL KILLER CELL; RADIATION RESPONSE;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; B7-H1 ANTIGEN; CELL LINE, TUMOR; GENETIC ENGINEERING; GPI-LINKED PROTEINS; GRANZYMES; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; MICE; MIDDLE AGED; RECEPTORS, IGG;

EID: 85007505136     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13411     Document Type: Article

References (35)

1. Gras Navarro A, Bjorklund AT, Chekenya M. Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol. 2015; 6:202
2. Paust S, Senman B, von Andrian UH. Adaptive immune responses mediated by natural killer cells. Immunol Rev. 2010; 235:286-296
3. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet. 2009; 373:1033-1040
4. Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy-advantages of the NK-92 cell line over blood NK cells. Front Immunol. 2016; 7
5. Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H. Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. OncoImmunology. 2013; 2:e26527
6. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994; 8:652-658
7. Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J, O'Reilly RJ. Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res. 1998; 4:2859-2868
8. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008; 10:625-632
9. Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, Suttorp M, Seifried E, Ottmann OG, Bug G. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013; 15:1563-1570
10. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frebourg T, Michel P, Sabourin JC, Boissiere-Michot F. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 2009; 27:1122-1129
11. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002; 99:754-758
12. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neupositive metastatic breast cancer. J Clin Oncol. 2008; 26:1789-1796
13. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007; 25:3712-3718
14. Kohrt HE, Houot R, Marabelle A, Cho HJ, Osman K, Goldstein M, Levy R, Brody J. Combination strategies to enhance antitumor ADCC. Immunotherapy. 2012; 4:511-527
15. Boissel L, Klingemann H, Campbell K, Nichols K, Toneguzzo F, Marcus P, Williams B, Keating A, Soon-Shiong P. An 'off the shelf,' GMP-grade, IL-2-independent NK cell line expressing the high-affinity Fc-receptor to augment antibody therapeutics. American Association for Cancer Research 107th Annual Meeting, April 16-20, 2016, New Orleans, LA. Cancer Res. 2016; 76
16. Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells-enhancement by therapeutic antibodies. PLoS One. 2007; 2:e326
17. Vanherberghen B, Olofsson PE, Forslund E, Sternberg-Simon M, Khorshidi MA, Pacouret S, Guldevall K, Enqvist M, Malmberg KJ, Mehr R, Onfelt B. Classification of human natural killer cells based on migration behavior and cytotoxic response. Blood. 2013; 121:1326-1334
18. Maki G, Klingemann HG, Martinson JA, Tam YK. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res. 2001; 10:369-383
19. Tam YK, Maki G, Miyagawa B, Hennemann B, Tonn T, Klingemann HG. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther. 1999; 10:1359-1373
20. Farsaci B, Donahue RN, Grenga I, Lepone LM, Kim PS, Dempsey B, Siebert JC, Ibrahim NK, Madan RA, Heery CR, Gulley JL, Schlom J. Analyses of pretherapy peripheral immunoscore and response to vaccine therapy. Cancer Immunol Res. 2016; 4:755-765
21. Gulley JL, Madan RA, Tsang KY, Jochems C, Marte JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res. 2014; 2:133-141
22. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med. 1998; 187:2065-2072
23. Alvarez IB, Pasquinelli V, Jurado JO, Abbate E, Musella RM, de la Barrera SS, Garcia VE. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis. J Infect Dis. 2010; 202:524-532
24. Benson DM, Jr., Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010; 116:2286-2294
25. Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004; 64:4664-4669
26. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol. 2005; 23:474-481
27. Zimmermann H, Weiland T, Nourse JP, Gandhi MK, Reinke P, Neuhaus R, Karbasiyan M, Gartner B, Anagnostopoulos I, Riess H, Trappe RU, Oertel S. Fcgamma-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder. J Immunol Res. 2014; 2014:264723
28. Oboshi W, Watanabe T, Matsuyama Y, Kobara A, Yukimasa N, Ueno I, Aki K, Tada T, Hosoi E. The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcgammaRIIIa-V158F genotypes in healthy Japanese subjects. Hum Immunol. 2016; 77:165-171
29. Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D, Zerbini A, Camisa R, Chernyschova N, Bisagni G, Loupakis F, Ruzzo A, Neri TM, et al. Role of immunoglobulin G fragment C receptor polymorphismmediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. Pharmacogenomics J. 2014; 14:14-19
30. Weng WK, Levy R. Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk Lymphoma. 2009; 50:723-727
31. Matlawska-Wasowska K, Gale JM, Nickl CK, Khalili P, Shirley B, Wilson BS, Vasef MA, Winter SS. Pyrosequencing for classification of human FcgammaRIIIA allotypes: a comparison with PCR-based techniques. Mol Diagn Ther. 2014; 18:665-673
32. Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015; 3:1148-1157
33. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol. 2013; 6:1
34. Ravetch JV, Perussia B. Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med. 1989; 170:481-497
35. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997; 90:1109-1114